Document Type : Research Paper

Authors

1 Ph.D. Student of Exercise Physiology, Urmia University

2 Associate Professor of Exercise Physiology, Urmia University

3 Assistant Professor of Exercise Physiology, Urmia University

Abstract

Considering the importance of glycemic balance adjustment in preventing cardiovascular complications of diabetes mellitus, regulation and control of blood glucose and insulin resistance is a very important issue. Including the protective factors that contrast with high blood glucose damage, can interoduce glucagon-like peptides (GLP-1), Neuregulin-1 (NRG-1), and interleukin-33 (IL-33) that this factor can be affected by exercise. Therefore, the purpose of this study was to investigate the effect of 8 weeks of resistance and aerobic interval training on levels of GLP-1, NRG-1 and IL-33 in type 2 diabetic women. 30 diabetic women (51.9 ± 5.9 years) were randomly devided into 3 groups (n=10 in each group), resistance training, aerobic interval training and volunteer control. Aerobic interval training was performed with intensity of 50-75% MHR and resistance training performed with intensity of 30-75% 1RM, 3 sessions per week for 8 weeks. The values of GLP-1, NRG-1 and IL-33 were measured by ELISA kit. For data, analysis used ANCOVA (P<0.05). The results of this study showed that resistance training compared to control group significantly increased (P = 0.007) the GLP-1. Aerobic (P = 0.037) and resistance training (P = 0.001) compared to the control group and resistance training compared to aerobic training (P = 0.008) significantly increased IL-33. NRG-1 changes were not significant in the two training groups. It seems that resistance training with positive regulation of GLP-1 and IL-33 has a better effect on glycemic control, blood glucose and ultimately improving cardiovascular conditions in type 2 diabetic women.

Keywords

Main Subjects

  1. O’Neill BT, Bhardwaj G, Penniman CM, Krumpoch MT, Beltran PAS, Klaus K, et al. Foxo transcription factors are critical regulators of diabetes-related muscle atrophy. Diabetes. 2019;68(3):556-70.
  2. Fuchsberger C, Flannick J, Teslovich TM, Mahajan A, Agarwala V, Gaulton KJ, et al. The genetic architecture of type 2 diabetes. Nature. 2016;536(7614):41-9.
  3. Hernandez AF, Green JB, Janmohamed S, D'Agostino Sr RB, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial. The Lancet. 2018;392(10157):1519-29.
  4. Jepsen SL, Albrechtsen NJW, Pedersen J, Engelstoft MS, Deacon CF, Holst JJ. GLP-1 secretion is increased upon blockade of the somatostatin receptor subtype 2 and 5 resulting in GLP-1 receptor-mediated lowering of blood glucose in mice. Am Diabetes Assoc; 2018;67(1):18-24.
  5. Holst JJ. Glucagonlike peptide 1: A newly discovered gastrointestinal hormone. Gastroenterology.1994;107(6)1848-55.  
  6. Bell GI, Santerre RF, Mullenbach GT. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature. 1983;302(5910):716-24.
  7. Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell Metab. 2016; 24(1):15-30.
  8. Armstrong M, Houlihan D, Rowe I, Clausen W, Elbrønd B, Gough S, et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: Individual patient data meta‐analysis of the LEAD program. ALIMENT PHARM THER. 2013;37(2):234-42.
  9. Lee J, Hong S-W, Chae SW, Kim DH, Choi JH, Bae JC, et al. Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J mice. PloS one. 2012;7(2):e31394-99.
  10. Trevaskis JL, Griffin PS, Wittmer C, Neuschwander-Tetri BA, Brunt EM, Dolman CS, et al. Glucagon-like peptide-1 (GLP-1) receptor agonism improves metabolic, biochemical and histopathological indices of nonalcoholic steatohepatitis (NASH) in mice. Am J Physiol Heart Circ Physiol.2012;302(7):762–772.
  11. Lee Y-S, Shin S, Shigihara T, Hahm E, Liu M-J, Han J, et al. Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis. Diabetes. 2007;56(6):1671-9.
  12. D'alessio DA, Kahn SE, Leusner CR, Ensinck JW. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. Clin Invest. 1994;93(5):2263-6.
  13. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. The Lancet. 2002;359(9309):824-30.
  14. Warbrick I, Rabkin SW. Effect of the peptides Relaxin, Neuregulin, Ghrelin and Glucagon-like peptide-1, on cardiomyocyte factors involved in the molecular mechanisms leading to diastolic dysfunction and/or heart failure with preserved ejection fraction. Peptides. 2019;111:33-41.
  15. Britsch S. The neuregulin-I/ErbB signaling system in development and disease. Baden-Württemberg : Springer Science & Business Media; 2007. p 37-63.
  16. Xu Y, Li X, Liu X, Zhou M. Neuregulin-1/ErbB signaling and chronic heart failure.  Adv Pharmacol. 2010;(59):31-51.
  17. Li B, Zheng Z, Wei Y, Wang M, Peng J, Kang T, et al. Therapeutic effects of neuregulin-1 in diabetic cardiomyopathy rats. Cardiovascular Diabetology.2011;69(1):10-15.
  18. Pentassuglia L, Timolati F, Seifriz F, Abudukadier K, Suter TM, Zuppinger C. Inhibition of ErbB2/neuregulin signaling augments paclitaxel-induced cardiotoxicity in adult ventricular myocytes. Exp. Cell Res. 2007;313(8):1588-601.
  19. Ennequin G, Boisseau N, Caillaud K, Chavanelle V, Etienne M, Li X, et al. Neuregulin 1 improves glucose tolerance in db/db mice. PloS One. 2015;10(7):e0130568.
  20. Rui T, Zhang J, Xu X, Yao Y, Kao R, Martin CM. Reduction in IL-33 expression exaggerates ischaemia/reperfusion-induced myocardial injury in mice with diabetes mellitus. Cardiovasc. Res. 2012;94(2):370-8.
  21. Miller AM, Asquith DL, Hueber AJ, Anderson LA, Holmes WM, McKenzie AN, et al. Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circulation Research. 2010;107(5):650-8.
  22. Milovanovic M, Volarevic V, Radosavljevic G, Jovanovic I, Pejnovic N, Arsenijevic N, et al. IL-33/ST2 axis in inflammation and immunopathology. Immunologic Research. 2012;52(1-2):89-99.
  23. Daousi C, Casson I, Gill G, MacFarlane I, Wilding J, Pinkney J. Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgrad Med J. 2006;82(966):280-4.
  24. Kemi OJ, Ellingsen Ø, Ceci M, Grimaldi S, Smith GL, Condorelli G, et al. Aerobic interval training enhances cardiomyocyte contractility and Ca2+ cycling by phosphorylation of CaMKII and Thr-17 of phospholamban. J. Mol. Cell. Cardiol. 2007;43(3):354-61.
  25. Crimi E, Ignarro LJ, Cacciatore F, Napoli C. Mechanisms by which exercise training benefits patients with heart failure. Nature Reviews Cardiology. 2009;6(4):292-9.
  26. Takada S, Masaki Y, Kinugawa S, Matsumoto J, Furihata T, Mizushima W, et al. Dipeptidyl peptidase-4 inhibitor improved exercise capacity and mitochondrial biogenesis in mice with heart failure via activation of glucagon-like peptide-1 receptor signalling. Cardiovascular Research. 2016;111(4):338-47.
  27. Park SH, Yoon JH, Seo DY, Kim TN, Ko JR, Han J. Resistance Exercise Training Attenuates the Loss of Endogenous GLP-1 Receptor in the Hypothalamus of Type 2 Diabetic Rats. Int. J. Environ. Res. 2019;16(5):830-9.
  28. Sayah A, Mohebbi H, Arazi H, Bahareh A. Are obese rats influenced by GLP1 and IR through aerobic exercise? A case study. Turkish Journal of Sport and Exercise. 2016;18(2):1-7.
  29. Liu Y, Liu S-x, Cai Y, Xie K-l, Zhang W-l, Zheng F. Effects of combined aerobic and resistance training on the glycolipid metabolism and inflammation levels in type 2 diabetes mellitus. J Phys Ther Sci 2015;27(7):2365-71.
  30. Cai M-X, Shi X-C, Chen T, Tan Z-N, Lin Q-Q, Du S-J, et al. Exercise training activates neuregulin 1/ErbB signaling and promotes cardiac repair in a rat myocardial infarction model. Life Sciences. 2016;149:1-9.
  31. Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circulation Research. 2010;107(6):810-7.
  32. Keating S, Johnson N, Mielke G, Coombes J. A systematic review and meta‐analysis of interval training versus moderate‐intensity continuous training on body adiposity. Obesity Reviews. 2017;18(8):943-64.
  33. Agha Alinejad H, Mehrabani J, AnsariDogahe R, Piri M. The influence of resistance, endurance, and combined resistance-endurance exercise training on interleukin-18 and C-reactive protein level in inactive female adolescents. Tabari Journal Of Preventive Medicine. 2016;2(1):38-47.
  34. Al-Shareefi AN, Al-Nimer MS, Aljebory HD, Hasan BT. Assessment of insulin resistant and the related cardio-metabolic factors in overweight-obese women presented with missed abortion, Baghdad, Iraq. Saudi Journal of Obesity. 2015;3(2):66-73.
  35. Brandt C, Pedersen BK. The role of exercise-induced myokines in muscle homeostasis and the defense against chronic diseases. BioMed Research International. 2010;1155,(10):1-6.
  36. Petersen AMW, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol. 2005;98(4):1154-62.
  37. Miller AM, Liew FY. The IL-33/ST2 pathway: A new therapeutic target in cardiovascular disease. Pharmacology & Therapeutics. 2011;131(2):179-86.
  38. Jeong JH, Lee YR, Park HG, Lee WL. The effects of either resveratrol or exercise on macrophage infiltration and switching from M1 to M2 in high fat diet mice. Journal of Exercise Nutrition & Biochemistry. 2015;19(2):65-72.
  39. Kuswanto W, Burzyn D, Panduro M, Wang KK, Jang YC, Wagers AJ, et al. Poor repair of skeletal muscle in aging mice reflects a defect in local, interleukin-33-dependent accumulation of regulatory T cells. Immunity. 2016;44(2):355-67.
  40. Shaabani M, Abolfathi F, Alizadeh AA. Serum glucagon-like peptide-1 changes in women with type 2 diabetes following a four weeks aerobic exercise. Iranian Journal of Diabetes and Obesity. 2016;8(2):61-6.
  41. Lee SS, Yoo JH, So YS. Effect of the low-versus high-intensity exercise training on endoplasmic reticulum stress and GLP-1 in adolescents with type 2 diabetes mellitus. J Phys Ther Sci. 2015;27(10):3063-8.
  42. Hallworth JR, Copeland JL, Doan J, Hazell TJ. The effect of exercise intensity on total PYY and GLP-1 in healthy females: A pilot study. Journal of Nutrition and Metabolism. 2017;2017(4823102)1-7.
  43. Goodyear LJ, Kahn BB. Exercise, glucose transport, and insulin sensitivity. Annual Review of Medicine. 1998;49(1):235-61.
  44. Urusova IA, Farilla L, Hui H, D'Amico E, Perfetti R. GLP-1 inhibition of pancreatic islet cell apoptosis. Trends in Endocrinology & Metabolism. 2004;15(1):27-33.
  45. Moondra V, Sarma S, Buxton T, Safa R, Cote G, Storer T, et al. Serum neuregulin-1β as a biomarker of cardiovascular fitness. The Open Biomarkers Journal. 2009;2:(1)18-24.
  46. Ennequin G, Boisseau N, Caillaud K, Chavanelle V, Gerbaix M, Metz L, et al. Exercise training and return to a well‐balanced diet activate the neuregulin 1/ErbB pathway in skeletal muscle of obese rats. The Journal of Physiology. 2015;593(12):2665-77.
  47. Iivanainen E, Paatero I, Heikkinen S-M, Junttila TT, Cao R, Klint P, et al. Intra-and extracellular signaling by endothelial neuregulin-1. Exp. Cell Res. 2007;313(13):2896-909.
  48. Shafi'i H, Sheikholeslami D. The effect of endurance, resistance and combination training on 1-sICAM levels and insulin resistance in passive women. Exercise Physiology. 2015;7 (27):85-100. (In Persian).
  49. Kazemi N, Kordi M.R, Nuri R, Kasraeian M. Effect of aerobic and resistance training on resistin & insulin levels in women with gestational diabetes. Sport Physiology. 2017;9(33):101-22. (In Persian).
  50. Keihanian A, Arazi H, Kargarfard M. The effect of eight weeks resistance and aerobic training on lipid profile and serum levels of hepatokine HFREP1 in Obese Men with Type 2 Diabetes. . 2019;10(40):85-98. (In Persian).